Healthy
Conditions
Brief summary
Study to investigate the effect of an inhibition of the renal cationic drug transporter on single dose pharmacokinetics of intravenous tiotropium in subjects in an age close to typical Chronic Obstructive Pulmonary Disease (COPD) population
Interventions
DRUGCimetidine + Tiotropium
DRUGRanitidine + Tiotropium
DRUGTiotropium
Sponsors
Boehringer Ingelheim
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
50 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy males or females * Age range from 50 to 65 years * Within 20% of their normal weight (Broca index)
Exclusion criteria
* Any finding of the medical examination (including blood pressure, puls rate and ECG) deviating from normal and of clinical relevance * Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders * Diseases of the central nervous system (such as epilepsy) or with psychiatric disorders or neurological disorders * History of orthostatic hypotension, fainting spells or blackouts * Chronic or relevant acute infections * History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator * Intake of a drug with a long half-life (≥ 24 hours) within ten half-lives of the respective drug before enrolment in the study or during the study (exclusion: ovarian hormone substitution) * Use of any drugs which might influence the results of the trial within four weeks prior to administration or during the trial, among these all non-selective β-blockers, cromolyn sodium, nedocromil sodium, oral β-adrenergics or long-acting β-adrenergics such as salmeterol and formoterol, and anticholinergic drugs including ATROVENT® (ipratropium) by oral inhalation or ATROVENT® Nasal Spray * Participation in another study with an investigational drug within two months prior to administration or during the trial * Smoker (\> 10 cigarettes or 3 cigars or 3 pipes/day) * Inability to refrain from smoking on study days * Alcohol abuse (\> 40 g/day) * Drug abuse * Blood donation (≥ 100 ml) within four weeks prior to administration or during the trial * Excessive physical activities within 5 days prior to administration or during the trial * Any laboratory value outside the reference range of clinical relevance * Subjects with known hypersensitivity to anticholinergic drugs * Subjects with known symptomatic prostatic hypertrophy or disturbed micturition * Subjects with known narrow-angle glaucoma In addition for female subjects (if appropriate): * Pregnancy * Positive pregnancy test * No adequate contraception e.g. oral contraceptives, sterilization, intra uterine pessary (IUP) * Inability to maintain this adequate contraception during the whole study period * Lactation period
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cmax of plasma levels of tiotropium after dosing | up to 8 hours after i.v. treatment |
| Area under the curve (AUC) 0-4h of the plasma levels of tiotropium after dosing | 0 - 4 hours after i.v. treatment |
| Urinary excretion 0-4h after dosing (Ae0-4h) | 0 - 4 hours after i.v. treatment |
| Renal clearance of tiotropium (CLR) | pre-dose, 0-4 h, 4-8 h, 8-12 h, 12-24 , 24-28 h, 38-72 h and 72-96 h after i.v. treatment |
Secondary
| Measure | Time frame |
|---|---|
| Changes in 12-lead electrocardiogram (ECG) | up to 24 h after i.v. treatment |
| AUC 0-8h of plasma levels of tiotropium after dosing | 0-8 hours after treatment |
| Changes from baseline in physical examination | Baseline, 4 - 8 days after last i.v. treatment |
| Changes in Blood Pressure and Pulse Rate | up to 4 - 8 days after last i.v. treatment |
| Urinary excretion 0-96h after dosing (Ae0-96h) | 0-96 hours after treatment |
| Occurrence of Adverse Events | up to 4 - 8 days after last i.v. treatment |
| Changes from baseline in Laboratory Tests | Baseline, 4 - 8 days after last i.v. treatment |
Outcome results
None listed